ACRS Aclaris Therapeutics Inc
Price (delayed)
$1.265
Market cap
$136.52M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.71
Enterprise value
$111.95M
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The
Highlights
ACRS's equity is up by 20% QoQ
ACRS's gross profit has plunged by 77% from the previous quarter and by 75% YoY
Aclaris Therapeutics's gross margin has shrunk by 67% QoQ and by 59% YoY
Key stats
What are the main financial stats of ACRS
Market
Valuations
Earnings
Shares outstanding
107.92M
Market cap
$136.52M
Enterprise value
$111.95M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.58
Price to sales (P/S)
5.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.98
Revenue
$18.72M
Gross profit
$3.26M
Operating income
-$139.43M
Net income
-$132.07M
EBIT
-$132.07M
EBITDA
-$131.26M
Free cash flow
-$20.2M
Per share
Balance sheet
Liquidity
EPS
-$1.71
EPS diluted
-$1.71
Free cash flow per share
-$0.26
Book value per share
$2.18
Revenue per share
$0.24
TBVPS
$2.85
Total assets
$220.33M
Total liabilities
$64.77M
Debt
$0
Equity
$155.55M
Working capital
$94.36M
Debt to equity
0
Current ratio
3.99
Quick ratio
3.61
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
-701.2%
Gross margin
17.4%
Net margin
-705.5%
Operating margin
-744.8%
Return on assets
-71.6%
Return on equity
-94.1%
Return on invested capital
-101.4%
Return on capital employed
-70%
Return on sales
-705.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACRS stock price
How has the Aclaris Therapeutics stock price performed over time
Intraday
6.3%
1 week
10.96%
1 month
-25.59%
1 year
8.12%
YTD
-48.99%
QTD
-17.32%
Financial performance
How have Aclaris Therapeutics's revenue and profit performed over time
Revenue
$18.72M
Gross profit
$3.26M
Operating income
-$139.43M
Net income
-$132.07M
Gross margin
17.4%
Net margin
-705.5%
Aclaris Therapeutics's operating margin has plunged by 193% from the previous quarter and by 87% YoY
ACRS's net margin has plunged by 149% YoY
The operating income has plunged by 103% from the previous quarter and by 12% YoY
ACRS's gross profit has plunged by 77% from the previous quarter and by 75% YoY
Growth
What is Aclaris Therapeutics's growth rate over time
Valuation
What is Aclaris Therapeutics stock price valuation
P/E
N/A
P/B
0.58
P/S
5.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.98
Aclaris Therapeutics's EPS has decreased by 35% YoY
ACRS's P/B is 85% below its 5-year quarterly average of 3.7 and 21% below its last 4 quarters average of 0.7
ACRS's equity is up by 20% QoQ
ACRS's P/S is 92% below its 5-year quarterly average of 61.2 but 7% above its last 4 quarters average of 4.6
The company's revenue fell by 40% YoY and by 31% QoQ
Efficiency
How efficient is Aclaris Therapeutics business performance
Aclaris Therapeutics's return on sales has shrunk by 148% YoY
The ROA has plunged by 78% YoY
The company's return on equity has shrunk by 78% YoY
Aclaris Therapeutics's return on invested capital has shrunk by 73% YoY
Dividends
What is ACRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACRS.
Financial health
How did Aclaris Therapeutics financials performed over time
Aclaris Therapeutics's total liabilities has soared by 61% YoY and by 24% from the previous quarter
Aclaris Therapeutics's quick ratio has decreased by 47% QoQ and by 6% YoY
ACRS's debt is 100% less than its equity
ACRS's equity is up by 20% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.